A clinical-stage pharmaceutical company developing novel therapeutics to treat important diseases such as non-alcoholic steatohepatitis (NASH) and various cancers. Our expertise in FASN enables us to break new ground in targeting dysfunctional metabolic pathways.

body

We’ve created a platform of proprietary, selective FASN inhibitors. Our lead product candidate TVB-2640 is an oral, highly potent, selective and reversible, first-in-class FASN inhibitor. TVB-2640 is rapidly absorbed in the human body with well-behaved pharmacokinetics.

Pipeline

FASN Inhibitor

Indication

Preclinical

Phase 1

Phase 2

Phase 3

TVB-2640

NASH

Title

58%

TVB-2640

Oncology

Title

58%

TVB-3567

Undisclosed

Title

22%

FASN Inhibitor – TVB-2640

Indication – NASH

Phase 2

Title

70%

FASN Inhibitor – TVB-2640

Indication – Oncology

Phase 2

Title

70%

FASN Inhibitor – TVB-3567

Indication – Undisclosed

Preclinical

Title

30%

Posters & Publications

September 6, 2019 in PUBLICATIONS

Fibroblast Growth Factor-21 and its Relationship to Human Liver Fat Synthesis; Impact of a New Therapeutic Agent

Read More
September 5, 2019 in PUBLICATIONS

The FASN inhibitor, TVB3664, Ameliorates NASH in a Murine Model

Read More
September 3, 2019 in PUBLICATIONS

Updated Results from a Prospective Phase 2 Study in Patients with First Relapse of High-grade Astrocytoma Using TVB-2640 in Combination with bevacizumab

Read More